华邦健康(002004) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥2,987,794,325.03, representing a year-over-year increase of 0.12%[2] - Net profit attributable to shareholders for Q3 2024 was ¥138,454,787.52, an increase of 17.55% compared to the same period last year[2] - The net profit after deducting non-recurring gains and losses for Q3 2024 was ¥140,915,870.79, up 32.20% year-over-year[2] - Total operating revenue for Q3 2024 reached ¥8,909,836,679.88, an increase from ¥8,853,071,322.91 in the same period last year, reflecting a growth of approximately 0.64%[11] - Total operating costs for Q3 2024 were ¥8,114,670,346.58, compared to ¥7,857,544,207.71 in the previous year, indicating an increase of about 3.27%[11] - The net profit for Q3 2024 was CNY 585,116,805.81, a decrease of 33.1% compared to CNY 875,142,530.13 in Q3 2023[12] - The total comprehensive income for the period was CNY 515,265,992.70, a decrease of 44.7% from CNY 931,186,872.20 in the same quarter last year[13] - Operating profit for Q3 2024 was CNY 784,087,500.30, down 29.9% from CNY 1,118,574,829.98 in Q3 2023[12] Assets and Liabilities - The total assets at the end of Q3 2024 amounted to ¥31,062,654,856.61, reflecting a growth of 1.09% from the end of the previous year[2] - Total liabilities amounted to ¥14,608,121,229.78, compared to ¥14,142,663,368.26 in the previous year, reflecting an increase of about 3.28%[11] - Non-current assets decreased slightly to ¥19,273,954,784.94 from ¥19,339,996,859.61, a decline of approximately 0.34%[10] - The total equity attributable to shareholders of the parent company was ¥10,108,873,174.98, a slight increase from ¥10,105,176,600.57[11] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥885,946,568.51, down 8.72% year-over-year[2] - The net cash flow from operating activities was CNY 885,946,568.51, a decrease of 8.7% compared to CNY 970,589,635.32 in the previous year[14] - The net cash flow from investing activities decreased by 73.26%, amounting to -¥709,689,608.23, primarily due to increased investments in financial products[5] - The company reported a significant increase in cash flow from investment activities, totaling CNY 12,047,317,646.97, compared to CNY 4,758,899,106.19 in the previous year[14] - Cash inflow from financing activities amounted to CNY 7.62 billion, slightly higher than CNY 7.27 billion in the previous year[15] - Net cash flow from financing activities was negative at CNY -53.86 million, an improvement from CNY -464.73 million year-over-year[15] - The ending balance of cash and cash equivalents stood at CNY 2.96 billion, down from CNY 3.09 billion year-over-year[15] Shareholder Information - The top shareholder, Tibet Huibang Technology Co., Ltd., holds 18.71% of the shares, totaling 370,449,804 shares[6] - Zhang Songshan, a significant shareholder, owns 5.91% of the shares, amounting to 117,095,583 shares, with 87,821,687 shares pledged[6] - The company has a total of 77,103 common shareholders as of the end of the reporting period[6] - The total number of preferred shareholders with restored voting rights is 0[6] - The company reported a total of 321,149,804 shares held by major shareholders through margin trading accounts[7] - The top ten shareholders collectively hold a significant portion of the company's equity, with the largest shareholder holding nearly 19%[6] Research and Development - Research and development expenses increased by 49.40%, reaching ¥80,016,653.11, indicating a focus on innovation[5] - Research and development expenses amounted to CNY 301,716,088.01, a decrease of 7.4% from CNY 325,832,813.94 in the same period last year[12] Other Information - The company has not disclosed any new product developments or market expansion strategies in this report[9] - There are no significant changes in the number of shares lent through margin trading compared to the previous period[8] - The company did not undergo an audit for the third quarter report[15]